Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.021 AUD | -4.55% | -22.22% | -40.00% |
05-16 | Chimeric Therapeutics Reopens Enrollment in Phase 1B Cell Therapy Study | MT |
05-02 | Chimeric Therapeutics Appoints COO; Shares Rise 4% | MT |
Business Summary
Managers
Managers | Title | Age | Since |
---|---|---|---|
Jennifer Chow
CEO | Chief Executive Officer | - | 20-11-30 |
Phillip Hains
DFI | Director of Finance/CFO | 64 | 23-07-11 |
Chief Tech/Sci/R&D Officer | - | 22-07-04 | |
Li Ren
CTO | Chief Tech/Sci/R&D Officer | - | 21-06-24 |
Jason B. Litten
CTO | Chief Tech/Sci/R&D Officer | 50 | 22-07-24 |
Elizabeth Chang
PRN | Corporate Officer/Principal | - | - |
Eliot Bourk
PRN | Corporate Officer/Principal | - | 21-02-22 |
Nathan Jong
SEC | Corporate Secretary | - | - |
Alison Gartner
PRN | Corporate Officer/Principal | - | - |
Corporate Officer/Principal | 60 | 22-02-02 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Lesley Russell
BRD | Director/Board Member | 63 | 20-08-27 |
Paul Hopper
FOU | Founder | 68 | 20-02-01 |
Phillip Hains
DFI | Director of Finance/CFO | 64 | 23-07-11 |
Eric Sullivan
BRD | Director/Board Member | - | 23-08-29 |
Jennifer Chow
CEO | Chief Executive Officer | - | 20-11-30 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 725,840,586 | 652,667,576 ( 89.92 %) | 0 | 89.92 % |
Company contact information
Chimeric Therapeutics Ltd. (Australia)
62 Lygon Street Level 3
3053, Carlton
+
http://www.chimerictherapeutics.comSector
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-40.00% | 13.16M | |
+8.29% | 113B | |
+10.21% | 106B | |
+0.41% | 22.27B | |
-11.90% | 22.22B | |
-5.99% | 19.43B | |
-37.36% | 17.87B | |
-5.17% | 17.24B | |
+7.70% | 14.29B | |
+37.65% | 12.52B |
- Stock Market
- Equities
- CHM Stock
- Company Chimeric Therapeutics Limited